Characteristics | RA | ReA | PsA | AS | CD | UC | SLE | pSS | sSS | SSc | PM/DM | HC |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total number of subjects | 207 | 22 | 34 | 33 | 20 | 22 | 40 | 16 | 28 | 22 | 43 | 69 |
Ageb, years | 54 | 23.5 | 46.5 | 44 | 33 | 35 | 37 | 50 | 53 | 53.5 | 41 | 38 |
25th percentile | 43.5 | 13.8 | 33 | 29.5 | 25.5 | 29.3 | 31.3 | 48 | 39.3 | 43.5 | 26 | 27 |
75th percentile | 63 | 33.5 | 54 | 51 | 43 | 45.8 | 52.3 | 63 | 63 | 58 | 58 | 41 |
Number of female/male subjects | 159/48 | 8/14 | 15/19 | 9/24 | 6/14 | 9/13 | 34/6 | 14/2 | 24/4 | 17/5 | 31/12 | 37/32 |
Disease durationb, years | 3 | 20 days | 5 | 2 | 3 | 4 | 4 | 2 | 3 | 2 | 1 | - |
25th percentile | 0.5 | 13 days | 3 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 0.3 | - |
75th percentile | 10 | 75 days | 7 | 4 | 6 | 7 | 6 | 4 | 8 | 5 | 2 | - |
Serum FSTL1 levels, μg/l | ||||||||||||
Geometric mean | 74.28 | 3.74 | 7.57 | 6.19 | 6.39 | 13.61 | 14.60 | 29.94 | 73.88 | 16.48 | 13.79 | 6.49 |
Lower 95% CI | 60.89 | 2.73 | 4.99 | 5.03 | 5.35 | 9.71 | 10.49 | 15.76 | 45.79 | 7.81 | 9.97 | 5.89 |
Upper 95% CI | 90.60 | 5.12 | 11.48 | 7.62 | 7.63 | 19.06 | 20.30 | 56.88 | 119.20 | 34.76 | 19.06 | 7.15 |
RSD (%) | 129.17 | 104.58 | 134.90 | 63.33 | 39.06 | 112.35 | 115.27 | 148.22 | 117.81 | 133.00 | 186.28 | 36.71 |
Median | 71.27 | 3.71 | 4.52 | 5.21 | 6.05 | 10.78 | 12.92 | 34.81 | 82.48 | 25.01 | 10.74 | 6.60 |
25th percentile | 25.51 | 2.49 | 3.47 | 3.67 | 4.92 | 7.48 | 6.84 | 10.51 | 23.48 | 3.38 | 6.76 | 5.28 |
75th percentile | 236.70 | 5.46 | 29.59 | 9.37 | 8.55 | 28.24 | 34.12 | 47.37 | 169.70 | 62.68 | 29.60 | 8.19 |
Above normal, %c | 87.43 | 9.09 | 26.47 | 18.18 | 5 | 36.36 | 52.5 | 68.75 | 96.43 | 54.55 | 48.84 | 4.3 |
P versus HC | <0.001 | <0.001 | 0.100 | 0.375 | 0.627 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.018 | - |
P versus RA | - | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.013 | 0.937 | <0.001 | <0.001 | <0.001 |